Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN)

Inclusion Criteria:

1. Male or female ≥ 18 years of age
2. Biopsy proven IgAN
3. Urine protein ≥ 0.75g/24 hours at Screening despite optimization with ACE inhibitorsor angiotensin receptor blockers (ARB)
4. eGFR ≥ 45 mL/min per 1.73 m2 or eGFR < 45 mL/min per 1.73 m2 and ≥ 30 mL/min per 1.73m2 with a kidney biopsy within 2 years of Screening showing < 50% tubulointerstitialfibrosis
5. Agree to comply with contraception requirements during and for 90 days after studycompletion.

Exclusion Criteria:

1. Any secondary IgAN as defined by the investigator
2. Patients who have undergone a kidney transplant
3. Any history of kidney disease other than IgAN
4. Any history of diabetes (Type 1 or Type 2)
5. Seated blood pressure > 140 mmHg (systolic) or > 90 mmHg (diastolic) at the ScreeningVisit. Patients must be on a stable dose and regimen of an ACE inhibitor or ARB for atleast 90 days
6. Pregnancy or breastfeeding.